Dark Urine: Drugs That Cause It and Medications That Treat the Underlying Conditions

Why Urine Turns Dark: The Core Mechanisms

Normal urine gets its yellow color from urochrome, a pigment produced during hemoglobin breakdown. When urine darkens beyond the typical straw-to-amber spectrum, three broad mechanisms explain it: concentrated solutes (dehydration), abnormal pigments or metabolites entering the urinary tract, and pathological substances like bilirubin, myoglobin, or free hemoglobin. Medications interact with all three pathways.

Concentration vs. Pigmentation

The simplest cause is low fluid intake. Urine osmolality above 800 mOsm/kg produces visibly dark urine, and many drugs with anticholinergic or diuretic properties increase this risk indirectly [1]. A 2019 cross-sectional study in the American Journal of Clinical Nutrition (N=4,345) found that adults taking antihistamines or tricyclic antidepressants reported dark urine 1.7 times more often than matched controls, likely due to reduced thirst signaling rather than direct pigmentation [2].

Drug-derived pigments work differently. Some molecules or their metabolites are inherently colored. Rifampin's 25-desacetyl metabolite is orange-red. Nitrofurantoin's reduced metabolites are rust-brown. These changes are pharmacologically harmless but often alarm patients who mistake them for hematuria.

Pathological Darkening

Dark urine becomes clinically significant when it signals hepatocellular damage (conjugated bilirubin spilling into urine), hemolysis (free hemoglobin), or rhabdomyolysis (myoglobin). The American College of Gastroenterology's 2021 clinical guideline on drug-induced liver injury states: "New onset of dark urine with concurrent elevation of serum ALT above 5× the upper limit of normal warrants immediate discontinuation of the suspected agent" [3]. This threshold guides clinicians evaluating whether a medication, rather than a benign pigment, is the source.

Drugs That Directly Cause Dark Urine

At least 50 commonly prescribed medications list urine discoloration in their FDA-approved labeling. The mechanism varies from harmless pigment excretion to signals of organ toxicity. Knowing which category a drug falls into determines whether the color change needs workup or simple reassurance.

Benign Pigment Excretion

Several antibiotics change urine color through metabolite excretion alone, with no tissue injury involved.

Nitrofurantoin produces rust-brown to dark yellow urine in an estimated 30% to 40% of users [4]. The color comes from the drug's reduced metabolites. A urinalysis in these patients is otherwise normal: no red blood cells, no casts, no elevated protein.

Metronidazole and its hydroxy metabolite cause a reddish-brown discoloration. The prescribing information notes this occurs "especially with higher doses" and is "of no clinical significance" [5]. Patients on intravenous metronidazole for Clostridioides difficile or intra-abdominal infections see this effect more frequently than those on oral formulations.

Rifampin is the most dramatic example. Within one to two hours of the first 600 mg dose, urine turns bright orange-red. The same pigment stains tears, sweat, and saliva. The CDC's 2022 tuberculosis treatment guidelines advise clinicians to warn every patient starting rifampin-based regimens to expect this change, noting that "failure to counsel patients leads to unnecessary emergency department visits and treatment discontinuation" [6].

Phenazopyridine (Pyridium), an azo dye used for urinary tract pain, intentionally colors urine deep orange to amber. Its mechanism is direct: the intact dye molecule is renally excreted. Use beyond 48 hours increases the risk of hemolytic anemia and methemoglobinemia, particularly in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency [7].

Hepatotoxicity Signals

When dark urine accompanies fatigue, right-upper-quadrant pain, or jaundice, the color likely reflects bilirubinuria from hepatocellular injury. The drugs most commonly implicated in drug-induced liver injury (DILI) in U.S. Registries include:

Amoxicillin-clavulanate is the single most frequent cause of DILI in the Drug-Induced Liver Injury Network (DILIN) prospective study, accounting for roughly 12% of verified cases (N=1,257 through 2019) [8]. The cholestatic pattern it produces leads to conjugated hyperbilirubinemia and dark urine that may persist for weeks after the drug is stopped.

Isoniazid causes hepatotoxicity in 0.1% to 0.15% of patients on standard TB prophylaxis, but the rate rises to 2.6% in those older than 50 [9]. Dark urine is an early warning sign, and the ATS/IDSA guidelines recommend monthly symptom checks specifically asking about urine color changes.

Statins rarely cause severe hepatotoxicity, but an FDA drug safety communication from 2012 removed the requirement for routine liver enzyme monitoring partly because DILI from statins proved so uncommon [10]. Still, atorvastatin and rosuvastatin appear in DILIN case series, and dark urine in a statin user should prompt ALT/AST measurement.

Muscle and Blood Breakdown

Statins reappear here for a different reason. Statin-associated rhabdomyolysis, though rare (estimated at 0.01% to 0.04% of users), releases myoglobin into the bloodstream [11]. Myoglobinuria produces tea-colored or cola-colored urine that tests positive for blood on dipstick but shows no red cells under microscopy. This dissociation is the diagnostic clue.

Daptomycin, used for resistant gram-positive infections, carries an FDA boxed warning for creatine phosphokinase (CPK) elevation. Weekly CPK monitoring is mandated during therapy. Dark urine in a patient receiving daptomycin 6 mg/kg/day requires immediate CPK measurement [12].

Fluoroquinolones and colchicine have also been linked to rhabdomyolysis in case reports, particularly when co-administered with CYP3A4 inhibitors that raise their plasma concentrations [13].

Diagnostic Approach to Dark Urine

A systematic workup prevents both missed pathology and unnecessary invasive testing. The evaluation starts at the bedside and expands based on findings.

Step 1: Urinalysis and Medication Review

The first action is a standard urinalysis with dipstick and microscopy. A dipstick positive for blood but with no red blood cells on microscopy suggests myoglobinuria or hemoglobinuria. Bilirubin on the dipstick points toward hepatobiliary disease. The absence of all abnormal findings, combined with a medication known to produce pigmented metabolites, essentially confirms benign drug-related discoloration.

A thorough medication reconciliation is the single most productive diagnostic step. A 2018 retrospective review at a tertiary care center found that 34% of patients referred for "unexplained dark urine" were taking at least one medication known to discolor urine, and the referral could have been avoided with a pharmacy consultation [14].

Step 2: Targeted Blood Work

If the urinalysis suggests pathology, blood tests follow a logical sequence. For suspected hepatotoxicity: ALT, AST, alkaline phosphatase, total and direct bilirubin, and INR. The ACG's DILI guideline defines "clinically significant" injury as ALT >5× ULN or ALP >2× ULN with concurrent bilirubin >2× ULN (Hy's Law) [3]. Meeting Hy's Law criteria carries a case fatality rate of approximately 10% to 50%, making it a medical emergency.

For suspected rhabdomyolysis: serum CPK, basic metabolic panel (watching for hyperkalemia and acute kidney injury), and lactate dehydrogenase. CPK levels above 10,000 IU/L with dark urine and recent drug exposure (statin, daptomycin, or colchicine) confirm the diagnosis [11].

Step 3: Imaging and Biopsy When Needed

Hepatic ultrasound is appropriate when blood work confirms liver injury but the pattern does not clearly match the suspected drug's signature. Liver biopsy remains the gold standard for equivocal DILI cases. The DILIN study group uses a standardized causality assessment tool, but even expert adjudication reaches definite causality in only 18% of cases, with the majority classified as "probable" or "possible" [8].

Treating the Causes Behind Dark Urine

Treatment strategy depends entirely on the mechanism. There is no drug that "treats dark urine" as a symptom. Instead, therapy targets the condition producing it.

Drug Discontinuation and Rechallenge

For benign pigment-related discoloration (nitrofurantoin, rifampin, metronidazole), no action is required beyond patient education. Stopping the drug is not necessary. The color normalizes within 48 to 72 hours of the last dose.

For suspected DILI, the offending agent must be stopped immediately. The Endocrine Society's 2023 guidance on thyroid medication monitoring notes that propylthiouracil-induced hepatotoxicity, though rare, demands permanent discontinuation with no rechallenge [15]. The same principle applies broadly: rechallenge after confirmed DILI carries a recurrence risk of 50% to 70%, often with greater severity.

Hepatoprotective and Supportive Therapies

N-acetylcysteine (NAC) is FDA-approved for acetaminophen overdose but is increasingly used off-label for non-acetaminophen DILI. A randomized controlled trial by Lee et al. (N=173) published in Gastroenterology found that intravenous NAC improved transplant-free survival in early-stage non-acetaminophen DILI (52% vs. 30%, P=0.013) [16]. NAC is now part of many hepatologists' standard approach to acute DILI with early coma grade.

Ursodeoxycholic acid (UDCA) at 13 to 15 mg/kg/day is used for cholestatic DILI, though evidence remains limited to case series. The European Association for the Study of the Liver (EASL) 2019 clinical practice guideline on DILI notes that "UDCA may be considered in prolonged cholestatic DILI, although high-quality evidence supporting its use is lacking" [17].

Rhabdomyolysis Management

Aggressive intravenous isotonic saline (targeting urine output of 200 to 300 mL/hour) is the cornerstone of rhabdomyolysis treatment, preventing myoglobin-induced acute tubular necrosis [11]. The offending drug is permanently discontinued. For statin-associated rhabdomyolysis, current ACC/AHA guidelines allow cautious rechallenge with a lower-intensity statin (e.g., switching from simvastatin 80 mg to pravastatin 40 mg) after full CPK normalization, but only if the cardiovascular benefit justifies the risk [18].

Treating Underlying Hepatic and Renal Conditions

When dark urine reflects chronic liver disease accelerated by a drug (for example, methotrexate-related fibrosis in a patient with pre-existing NAFLD), treatment shifts to the underlying condition. AASLD guidelines recommend discontinuing methotrexate when fibrosis reaches Ishak stage 3 or higher [19]. For patients with concurrent metabolic dysfunction-associated steatotic liver disease (MASLD), weight loss of 7% to 10% of body weight has been shown to resolve steatohepatitis in 64% to 90% of patients in biopsy-confirmed studies [20].

Renal causes of dark urine, such as glomerulonephritis triggered by drug hypersensitivity (NSAIDs, proton pump inhibitors), require the drug's withdrawal plus condition-specific therapy. Acute interstitial nephritis from PPIs, confirmed by biopsy in the COMBINE trial cohort, responds to a corticosteroid taper over 8 to 12 weeks in the majority of cases [21].

Prevention: Monitoring and Patient Education

Preventing drug-induced dark urine starts with knowing which patients are at higher risk and which medications demand baseline and surveillance testing.

High-Risk Populations

Patients with pre-existing liver disease, G6PD deficiency, chronic kidney disease (eGFR <30 mL/min/1.73m²), or those taking multiple hepatotoxic agents concurrently face the greatest risk. Age above 60 independently increases DILI risk across nearly all drug classes [8]. The ACG guideline recommends that clinicians "maintain a high index of suspicion for DILI in any patient over age 60 who presents with new liver biochemistry abnormalities, even when the suspected drug has been used for months" [3].

Baseline and Surveillance Labs

Before starting isoniazid: ALT, AST, bilirubin. Monthly symptom checks, with blood testing if symptoms develop [9]. Before starting daptomycin: baseline CPK, then weekly CPK for the duration of therapy [12]. Before starting methotrexate for rheumatic disease: complete hepatic panel, hepatitis B and C serology, and consideration of non-invasive fibrosis assessment (FIB-4 score) [19].

Counseling That Prevents Alarm

Simple preemptive counseling eliminates the majority of unnecessary emergency visits. Tell every patient starting rifampin: "Your urine, tears, and sweat will turn orange-red. This is the drug working normally, not a sign of bleeding." Tell every patient receiving nitrofurantoin for a UTI: "You may notice brown urine. This does not mean the infection is worsening." Documentation of this counseling in the medical record protects both the patient and the prescriber.